Clinical trial · Interventional
Robot-Assisted Ultrasound for Thermal Ablative Therapy in Treating Patients With Small Kidney Masses Undergoing Surgery
Robot-Assisted Laparoscopic HIFU (High-Intensity Focused Ultrasound) for Thermal Ablative Therapy of Small Renal Mass: Corroborating With Robot-Assisted Laparoscopic Partial Nephrectomy Specimens
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): No funding
Summary
Brief summary (as posted)
This clinical trial studies a type of ultrasound called robot-assisted laparoscopic high-intensity focused ultrasound for performing thermal ablative therapy, or sound wave therapy, in treating patients with small kidney masses undergoing partial removal of the kidney. The robot-assisted ultrasound probe takes images of the kidney to help doctors locate the mass. The probe then uses high frequency sound waves to target and ablate (or destroy) the kidney mass, which may be a cancerous tumor or benign tissue. Surgery is then performed to remove the part of the kidney with the mass. Robot-assisted laparoscopic high-intensity focused ultrasound for thermal ablative therapy may be safer and help doctors see the tumor better when performing kidney surgery.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Carcinoma | Kidney Carcinoma | ALIAS | 0.90 |
| Renal Mass | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| High-Intensity Focused Ultrasound Ablation | Procedure | — | UNRESOLVED |
| Robot-Assisted Laparoscopic Surgery | Procedure | — | UNRESOLVED |
| Sonatherm 600i Ultrasonic Lesion Generating System | Device | — | UNRESOLVED |
| Therapeutic Laparoscopic Surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment (robot-assisted laparoscopic HIFU)
- description
- Patients undergo robot-assisted laparoscopic HIFU thermal ablative therapy during partial nephrectomy.
- interventionNames
- Procedure: Robot-Assisted Laparoscopic Surgery
- Procedure: High-Intensity Focused Ultrasound Ablation
- Procedure: Therapeutic Laparoscopic Surgery
- Device: Sonatherm 600i Ultrasonic Lesion Generating System
Primary outcomes (2)
- measure
- Planned ablation volume
- timeFrame
- Baseline (day of surgery)
- description
- Ablation area of the kidney mass will be compared to the planned area under histopathologic review. Analyzed using a one-sided one sample T-test.
- measure
- Necrosis volume
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Presence of an enhancing solid renal mass =\< 3.0 cm on radiological examination * Tumors with a depth of not greater than 3.0 cm from a laparoscopically accessible surface-meaning no part of the tumor should be deeper than 3.0 cm from the surface * Patients with solitary kidneys, bilateral renal tumors, compromised renal function (baseline creatinine \> 1.4) * Subjects must have given written informed consent * Previous chemotherapy, and/or biological therapy for cancer are permitted provided that the acoustic properties of the tumor were not affected, but the subject should have recovered from the effects of these or of any prior surgery * Subjects must be free of any clinically significant disease other than cancer that would interfere with the study evaluations * Absolute neutrophil count (ANC) \>= 1500 mm\^-3 * Platelet count \>= 100,000 mm\^-3 * Hemoglobin \>= 10 g/dl * Prothrombin time (PT) =\< 1.5 times upper limit of laboratory normal (ULN) * Activated partial thromboplastin time =\< 1.5 times ULN * Urea and serum creatinine \< 2.5 times ULN * Total bilirubin \< 1.5 times ULN * Aspartate aminotransferase (AST) =\< 3 times ULN * Alkaline phosphatase \< 2 times ULN, unless arising from bone Exclusion Criteria: * \< 90% solid component on screening cross-sectional imaging * Subjects deemed unsuitable candidates and not medically optimized for partial nephrectomy * Tumors greater than 3.0 cm at their widest point * Subjects with tumors lying \< 1 cm from sensitive structures such as the ureter, renal vessels or adjacent bowel * Subjects on concurrent anticoagulant, or immunosuppressive medication * Subjects on anti-cancer medication whether biologic or pharmaceutical * Women who are pregnant or nursing (pregnancy test to be performed within 24 hours prior to HIFU treatment) * Subjects assessed by consultant anesthetist as unsuitable for general anesthetic * Subjects having had prior ablation therapy on the same tumor
References
Publications (0)
Data not yet available